Editas Medicine, Inc. announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patient with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65thAmerican Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online. Key data from patients treated in the RUBY trial and in the EdiTHAL trial will be shared, including: RUBY; Clinical data on 11 patients, including two patients with at least 12 months follow-up and an additional four patients with at least five months follow-up; Efficacy data, including total hemoglobin, fetal hemoglobin, and vaso-occlusive events, or VOEs. Higher levels of fetal hemoglobin (HbF) inhibit HbS polymerization, thus reducing the manifestation of sickling.

About EDIT-301: EDIT-301 is an experimental gene editing medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thAL trial. Enrolled patients will receive a single administration of EDIT-301.